Key result
A peptide fragment of the beta-1 adrenergic receptor (ADRB1) was identified that elicits CD4+ T-cell responses after myocardial infarction in patients with a defined HLA haplotype.
Why the study?
T-cells contribute to myocardial diseases like MI and HF, but the cardiac antigens triggering heart-directed T-cell responses in patients have remained unknown.
Observational
The identification of a specific ADRB1 peptide fragment that triggers CD4+ T-cell responses post-myocardial infarction provides a novel target for monitoring antigen-specific immune responses in cardiac disease.
Hypothesis-generating for HLA-specific ADRB1 T-cell monitoring post-MI; does not yet support clinical adoption.
T-cells contribute to pathophysiological processes in myocardial diseases, including myocardial infarction (MI) and heart failure (HF). Antigen-specificity is a hallmark of T-cell responses but the cardiac antigens that trigger heart-directed T-cell responses in patients have not yet been uncovered, thus posing a roadblock to translation. In the present exploratory study, we identified a peptide fragment of the beta-1 adrenergic receptor (ADRB1) that elicits CD4 + T-cell responses after myocardial infarction in patients with a defined HLA haplotype. Our observations may advance the development of tools to monitor other antigen-specific immune responses in patients.
No takes yet. Share an insight, caveat, or question.
Hapke et al. (2022) conducted an observational in Myocardial infarction. Peptide fragment of the beta-1 adrenergic receptor (ADRB1) was evaluated on CD4+ T-cell responses. A peptide fragment of the beta-1 adrenergic receptor (ADRB1) was identified that elicits CD4+ T-cell responses after myocardial infarction in patients with a defined HLA haplotype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: